National CMOP ZINC OXIDE 20% OINT AND ARTIFICIAL SALIVA ORAL SPRAY

The Department of Veterans Affairs National Consolidated Mail Outpatient Pharmacy (CMOP) Procurement Office is seeking pharmaceutical products through RFQ 36C77025Q0288, specifically Artificial Saliva Oral Spray (NDC 50930-0098-08) and Zinc Oxide 20% Ointment (NDC 71399-0245-02/71399-0245-06) for distribution to multiple CMOP facilities. The procurement targets facilities in Tucson, Lancaster, Murfreesboro, Hines, and Charleston, with delivery requirements structured over a three-month period beginning 10 days after receipt of order. Vendors must be registered in SAM.gov and submit comprehensive documentation including SF1449 forms, pricing schedules, state wholesale distributor licenses, original equipment manufacturer documentation, and Buy American Act certificates. The presolicitation notice was issued on September 3, 2025, with vendor responses due by September 10, 2025, at 4:00 PM CST. All submissions must be completed via email to the designated procurement office, with the evaluation process focusing on compliance with pharmaceutical distribution requirements and pricing competitiveness.

This opportunity is designated as a total small business set-aside under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), restricting participation to qualified small business entities in the pharmaceutical sector. The procurement involves estimated delivery quantities ranging from 384 to 2,640 units per facility across the five designated CMOP locations, though specific award values or total contract amounts are not disclosed in the presolicitation documentation. Delivery will be executed through a staggered monthly distribution schedule over the three-month contract period, ensuring consistent supply chain management across all participating facilities. The contract structure emphasizes pharmaceutical supply chain compliance, requiring vendors to maintain appropriate state licensing and demonstrate manufacturing authenticity through OEM documentation. No incumbent contractors or current service providers are identified in the available documentation, suggesting this may represent either a new procurement or a competitive recompetition of existing pharmaceutical supply arrangements.